The results of a clinical trial did not provide support for the use of orally administered valproic acid for the treatment of autosomal dominant retinitis pigmentosa, as it did not outperform a placebo over the course of 12 months.
The multicenter, prospective, interventional, placebo-controlled, double-masked, randomized phase 2 clinical trial included 90 participants who received either 500 mg to 1,000 mg of oral valproic acid (VPA) daily or a placebo for 12 months. Researchers evaluated the change in visual field area between baseline and 1 year as the primary outcome (Read more...)

Full Story →

The results of a clinical trial did not provide support for the use of orally administered valproic acid for the treatment of autosomal dominant retinitis pigmentosa, as it did not outperform a placebo over the course of 12 months.
The multicenter, prospective, interventional, placebo-controlled, double-masked, randomized phase 2 clinical trial included 90 participants who received either 500 mg to 1,000 mg of oral valproic acid (VPA) daily or a placebo for 12 months. Researchers evaluated the change in visual field area between baseline and 1 year as the primary outcome (Read more...)

Full Story →